CN109529061A - Purposes of the fat emulsion as photoacoustic imaging contrast agent - Google Patents
Purposes of the fat emulsion as photoacoustic imaging contrast agent Download PDFInfo
- Publication number
- CN109529061A CN109529061A CN201811439124.4A CN201811439124A CN109529061A CN 109529061 A CN109529061 A CN 109529061A CN 201811439124 A CN201811439124 A CN 201811439124A CN 109529061 A CN109529061 A CN 109529061A
- Authority
- CN
- China
- Prior art keywords
- fat emulsion
- photoacoustic imaging
- contrast agent
- purposes
- imaging contrast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 70
- 238000003384 imaging method Methods 0.000 title claims abstract description 56
- 239000002872 contrast media Substances 0.000 title claims abstract description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- 238000001990 intravenous administration Methods 0.000 claims abstract description 9
- 239000000787 lecithin Substances 0.000 claims abstract description 9
- 229940067606 lecithin Drugs 0.000 claims abstract description 9
- 235000010445 lecithin Nutrition 0.000 claims abstract description 9
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 9
- 239000003549 soybean oil Substances 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 235000011187 glycerol Nutrition 0.000 claims abstract description 5
- 210000003462 vein Anatomy 0.000 claims abstract description 5
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 239000013589 supplement Substances 0.000 abstract description 5
- 230000003287 optical effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000002468 fat body Anatomy 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention proposes purposes of the fat emulsion as photoacoustic imaging contrast agent, belongs to biology and optical field.Fat emulsion can enhance the photoacoustic signal and picture contrast of tissue.Fat emulsion is imaged for animal or human body.Fat emulsion is used for animal imaging, and fat emulsion enters in animal body through tail vein injection.When fat emulsion is imaged for human body, fat emulsion intravenous administration enters in human body.Fat emulsion is made of soybean oil, lecithin and glycerol, and 20% fat emulsion soybean oil containing 200g, 12g lecithin, the 22g glycerol of every 1000ml.The purposes of fat emulsion of the invention as photoacoustic imaging contrast agent can enhance tissue photoacoustic imaging contrast significantly.In addition, fat emulsion is clinically often used as the supplement medicine of intravenous nutrition, compared to other photoacoustic imaging contrast agent, production method is simple, at low cost, and the biological safety with height, is used as photoacoustic imaging contrast agent with huge application potential.
Description
Technical field
Purposes the present invention relates to biology and optical field more particularly to fat emulsion as photoacoustic imaging contrast agent.
Background technique
Photoacoustic imaging is the new bio medical imaging side of a kind of non-invasive and unionized formula developed in recent years
Method.Photoacoustic imaging combines in the imaging of pure optical texture the excellent of deep penetration characteristic in high selection characteristic and the imaging of pure ultrasonic tissue
Point, can be obtained high-resolution organization chart picture, and photoacoustic signal transmitting contains much information, and can provide form and functional information.
Compared to other optical image technologies, such as optical coherence tomography, photoacoustic imaging can be imaged deep tissues.But
It is that internal some intrinsic chromophore such as hemoglobins are very weak in the absorption of near infrared band, leads to the contrast of organization internal
It is very weak, therefore the research of photoacoustic imaging contrast agent has attracted the attention of many people in recent years.Current existing photoacoustic imaging
Contrast agent includes that the indoles mountain valley with clumps of trees and bamboo is green and nano Au particle has an apparent photoacoustic imaging reinforcing effect, but their bio-safety
Property it is still unknown, and preparation method is complicated, and cost religion is high.
Fat emulsion is made of soybean oil, lecithin and glycerol, and preparation process is simple, cheap, is easy to obtain.And
It is clinically usually used as the supplement medicine of intravenous nutrition, provides energy and amino acid for body, therefore biological safety can obtain
To guarantee.
Therefore, it for the deficiency of existing photoacoustic imaging contrast agent, provides a kind of with high biological safety and optoacoustic
The novel type radiographic contrast of image contrast humidification has huge application potential.
Summary of the invention
Purposes the object of the present invention is to provide fat emulsion as photoacoustic imaging contrast agent.
Above-mentioned purpose of the invention is realized by following technological means.
Purposes of the fat emulsion as photoacoustic imaging contrast agent is provided.
Preferably, the fat emulsion can enhance the photoacoustic signal and picture contrast of tissue.
Preferably, fat emulsion is imaged for animal or human body.
Fat emulsion is used for animal imaging as a preferred method, and fat emulsion enters in animal body through tail vein injection.
Preferably, when fat emulsion is used for animal imaging, injection volume 20ml/kg.
As another preferred embodiment, fat emulsion intravenous administration enters in human body when fat emulsion is imaged for human body.
Further, the fat emulsion is made of soybean oil, lecithin and glycerol, and 20% Fat Emulsion of every 1000ml
Agent soybean oil containing 200g, 12g lecithin, 22g glycerol.
Further, the wave-length coverage of laser used in photoacoustic imaging is near infrared band.
Further, the wave-length coverage of laser used in photoacoustic imaging is in 680~900nm.
Further, the wavelength of laser used in photoacoustic imaging is 760nm.
Another preferred, the wave-length coverage of laser used in photoacoustic imaging is in visible light wave range.
The purposes of fat emulsion of the invention as photoacoustic imaging contrast agent can enhance tissue photoacoustic imaging pair significantly
Degree of ratio.In addition, fat emulsion is clinically often used as the supplement medicine of intravenous nutrition, compared to other photoacoustic imaging radiographies
Agent, production method is simple, at low cost, and the biological safety with height, is used as photoacoustic imaging contrast agent with huge
Big application potential.
Detailed description of the invention
Using attached drawing, the present invention will be further described, but the content in attached drawing does not constitute any limitation of the invention.
Fig. 1 is the optoacoustic intensity map of fat emulsion of the invention under different wave length laser irradiation;
Fig. 2 is the photoacoustce signal intensity of fat emulsion of the invention with the increased curve graph of concentration;
Fig. 3 is the photoacoustic image of nude mice brain and kidney portion: a injects protocerebral region, and b injects back brain, and c injects pronephridiostome portion, d note
Penetrate rear kidney portion.
Specific embodiment
The invention will be further described with the following Examples.
Embodiment 1.
Purposes of the fat emulsion as photoacoustic imaging contrast agent, fat emulsion enhance the photoacoustic signal of tissue, and tissue
With the contrast of background.Fat emulsion is made of soybean oil, lecithin and glycerol, and 20% fat emulsion of every 1000ml contains 200g
Soybean oil, 12g lecithin, 22g glycerol.Fat emulsion is clinically often used as the supplement medicine of intravenous nutrition, with height
Biological safety.
Fat emulsion is imaged for animal or human body.When fat emulsion is used for animal imaging, the fat emulsion of 20ml/kg is passed through
Tail vein injection enters in animal body.When fat emulsion is imaged for human body, fat emulsion intravenous administration enters in human body.
The wave-length coverage of laser used in photoacoustic imaging is near infrared band.Preferably, the wavelength of laser used in photoacoustic imaging
Range 680~900nm near infrared band, with wavelength be 760nm more preferably.
It should be noted that the wave-length coverage of laser used in photoacoustic imaging can also be in visible light wave range.
The purposes of fat emulsion of the invention as photoacoustic imaging contrast agent can enhance tissue photoacoustic imaging pair significantly
Degree of ratio.In addition, fat emulsion is clinically often used as the supplement medicine of intravenous nutrition, compared to other photoacoustic imaging radiographies
Agent, production method is simple, at low cost, and the biological safety with height, is used as photoacoustic imaging contrast agent with huge
Big application potential.
Embodiment 2.
20% medical fat emulsion injection is diluted to 15%, 10%, 5% with physiological saline, check they
Photoacoustic signal under 680nm, 700nm, 730nm, 760nm, 780nm, 800nm, 820nm, 850nm, 875nm pulse laser.Knot
Fruit show fat emulsion have strongest photoacoustic signal under 760nm laser irradiation, as shown in Figure 1, and photoacoustce signal intensity with
The increase of fat emulsion concentration and show linear increase, as shown in Fig. 2, proving that fat emulsion has as optoacoustic using this
The potentiality of image-forming contrast medium.
Embodiment 3.
Nude mice is anaesthetized with 5% isoflurane, carries out the Photoacoustic tomography of brain, kidney portion;Then through tail vein injection
The fat emulsion that 20ml/kg concentration is 20% carries out photoacoustic imaging to brain, kidney portion later, observes fat emulsion to animal groups
The photoacoustic imaging reinforcing effect knitted.Before injecting fat emulsion, nude mice cerebral vessels signal, brain parenchym signal and nephridial tissue
Signal is weaker, as shown in a, c in Fig. 3.As shown in b, d in Fig. 3, after injecting fat emulsion, nude mice cerebral vessels, brain parenchym
And the photoacoustic signal of kidney has obtained apparent enhancing, shows to participate in sanguimotor fat emulsion and enhances brain and kidney portion
Radiography.Therefore, fat emulsion can be used as the contrast agent of photoacoustic imaging to enhance the photoacoustic signal of animal tissue.
Finally it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should be managed
Solution, can with modification or equivalent replacement of the technical solution of the present invention are made, without departing from technical solution of the present invention essence and
Range.
Claims (10)
1. purposes of the fat emulsion as photoacoustic imaging contrast agent.
2. purposes of the fat emulsion according to claim 1 as photoacoustic imaging contrast agent, it is characterised in that: the fat
The photoacoustic signal and picture contrast of emulsion enhancing tissue.
3. purposes of the fat emulsion according to claim 2 as photoacoustic imaging contrast agent, it is characterised in that: fat emulsion
It is imaged for animal or human body.
4. purposes of the fat emulsion according to claim 2 as photoacoustic imaging contrast agent, it is characterised in that: fat emulsion
For animal imaging, fat emulsion enters in animal body through tail vein injection.
5. purposes of the fat emulsion according to claim 4 as photoacoustic imaging contrast agent, it is characterised in that: fat emulsion
When for animal imaging, injection volume 20ml/kg.
6. purposes of the fat emulsion according to claim 2 as photoacoustic imaging contrast agent, it is characterised in that: fat emulsion
When for human body imaging, fat emulsion intravenous administration enters in human body.
7. the purposes according to fat emulsion described in claim 3 to 6 any one as photoacoustic imaging contrast agent, feature exist
In: the fat emulsion is made of soybean oil, lecithin and glycerol.
8. purposes of the fat emulsion according to claim 7 as photoacoustic imaging contrast agent, it is characterised in that: every 1000ml
20% fat emulsion soybean oil containing 200g, 12g lecithin, 22g glycerol.
9. purposes of the fat emulsion according to claim 2 as photoacoustic imaging contrast agent, it is characterised in that: photoacoustic imaging
The wave-length coverage of laser used is near infrared band.
10. purposes of the fat emulsion according to claim 2 as photoacoustic imaging contrast agent, it is characterised in that: optoacoustic at
As the wave-length coverage of laser used is in visible light wave range.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811439124.4A CN109529061A (en) | 2018-11-29 | 2018-11-29 | Purposes of the fat emulsion as photoacoustic imaging contrast agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811439124.4A CN109529061A (en) | 2018-11-29 | 2018-11-29 | Purposes of the fat emulsion as photoacoustic imaging contrast agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109529061A true CN109529061A (en) | 2019-03-29 |
Family
ID=65850755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811439124.4A Pending CN109529061A (en) | 2018-11-29 | 2018-11-29 | Purposes of the fat emulsion as photoacoustic imaging contrast agent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109529061A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436428A (en) * | 1979-07-06 | 1984-03-13 | Fuji Electric Co., Ltd. | Photoacoustic spectrometer |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
WO2014055539A1 (en) * | 2012-10-01 | 2014-04-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle emulsions |
-
2018
- 2018-11-29 CN CN201811439124.4A patent/CN109529061A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436428A (en) * | 1979-07-06 | 1984-03-13 | Fuji Electric Co., Ltd. | Photoacoustic spectrometer |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
WO2014055539A1 (en) * | 2012-10-01 | 2014-04-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle emulsions |
Non-Patent Citations (4)
Title |
---|
C. G. A. HOELEN等: "Three-dimensional photoacoustic imaging of blood vessels in tissue", 《OPTICS LETTERS》 * |
MATTI KINNUNEN等: "Frequency spectrum analysis of pulsed photoacoustic signals in Intralipid", 《PROC. OF SPIE》 * |
张瑶华等: "《中国常用药品集》", 30 June 2006, 上海交通大学出版社 * |
郭建: "***及其肿瘤的组织光学模型与Monte Carlo模拟", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Park et al. | Deep tissue photoacoustic imaging of nickel (II) dithiolene-containing polymeric nanoparticles in the second near-infrared window | |
Yao et al. | Multiscale functional and molecular photoacoustic tomography | |
Needles et al. | Development and initial application of a fully integrated photoacoustic micro-ultrasound system | |
Deán‐Ben et al. | Volumetric hand‐held optoacoustic angiography as a tool for real‐time screening of dense breast | |
Hariri et al. | In vivo photoacoustic imaging of chorioretinal oxygen gradients | |
WO2009037464A1 (en) | Imaging apparatus and method | |
Lee et al. | Positional relationship of superior and inferior labial artery by ultrasonography image analysis for safe lip augmentation procedures | |
US20150313540A1 (en) | Improved Methods of Assessing Metabolic Function | |
Zhang et al. | Photoacoustic imaging of living mice enhanced with a low-cost contrast agent | |
Wang et al. | Photoacoustic-guided photothermal therapy by mapping of tumor microvasculature and nanoparticle | |
Gao et al. | Near-infrared dye-loaded magnetic nanoparticles as photoacoustic contrast agent for enhanced tumor imaging | |
Wang et al. | Ingestible roasted barley for contrast-enhanced photoacoustic imaging in animal and human subjects | |
Tian et al. | Phosphotungstate acid doped polyanilines nanorods for in situ NIR-II photothermal therapy of orthotopic hepatocellular carcinoma in rabbit | |
Perekatova et al. | Quantitative techniques for extraction of blood oxygenation from multispectral optoacoustic measurements | |
CN104117073B (en) | A kind of Double-mode imaging nano-micelle and its production and use | |
Fenton et al. | Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single-and multifraction irradiation | |
CN109529061A (en) | Purposes of the fat emulsion as photoacoustic imaging contrast agent | |
Lee et al. | Photoacoustic imaging in nanomedicine | |
CN102940895B (en) | Nanobubble solution, preparation method and applications thereof | |
Pramanik et al. | Looking Deeper: Multimodal and contrast-enhanced photoacoustic imaging offer a clearer view within tissues for more accurate diagnosis | |
CN105283202B (en) | Hypotonic solution for lymph node detection | |
CN105327365B (en) | A kind of magneto-optic bimodal imaging nano-probe and its application | |
KR20160142199A (en) | Contrast composition for photoacoustic imaging and method for photoacoustic imaging using the same | |
Oraevsky | 3D optoacoustic tomography: From molecular targets in mouse models to functional imaging of breast cancer | |
CN105848713A (en) | Carbon monoxide poisoning resolving device, jacket for carbon monoxide poisoning treatment having said device, and catheter for carbon monoxide poisoning treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |
|
RJ01 | Rejection of invention patent application after publication |